Literature DB >> 29153200

Adrenomedullin as a Biomarker of Heart Failure.

Toshio Nishikimi1, Yasuaki Nakagawa2.   

Abstract

Adrenomedullin (AM) is a vasodilatory peptide originally discovered in human pheochromocytoma tissue. Although AM is highly expressed in the adrenal glands, heart, lungs, and kidneys, vascular endothelium and smooth muscle are thought to be the main source of plasma AM. The AM precursor is processed to AM-glycine, which is then converted to AM-mature through C-terminal amidation. In this process, mid-regional pro-adrenomedullin (MR-proAM) is also produced. Plasma AM, AM-mature, AM-glycine, and MR-proAM levels are all higher in patients with heart failure than healthy subjects in proportional to the disease severity. All molecular forms of AM are prognostic markers for heart failure.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenomedullin; B-type natriuretic peptide (BNP); Heart failure; Mid-regional pro-adrenomedullin

Mesh:

Substances:

Year:  2017        PMID: 29153200     DOI: 10.1016/j.hfc.2017.08.006

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  10 in total

1.  Adrenomedullin inhibits tumor metastasis and is associated with good prognosis in triple-negative breast cancer patients.

Authors:  Li-Li Liu; Shi-Lu Chen; Yu-Hua Huang; Xia Yang; Chun-Hua Wang; Jie-Hua He; Jing-Ping Yun; Rong-Zhen Luo
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

Review 2.  Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers.

Authors:  Alexander E Berezin; Alexander A Berezin
Journal:  Dis Markers       Date:  2020-06-12       Impact factor: 3.434

3.  Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure.

Authors:  Henrike Arfsten; Philipp E Bartko; Noemi Pavo; Gregor Heitzinger; Julia Mascherbauer; Christian Hengstenberg; Martin Hülsmann; Georg Goliasch
Journal:  Eur J Clin Invest       Date:  2019-10-09       Impact factor: 4.686

4.  Relationship Between Serum Concentration of Adrenomedullin and Myocardial Ischemic T Wave Changes in Patients With Lung Cancer.

Authors:  Chen Wu; Da-Wei Lin; Yi-Wen Jiang; Feng Jiang; Zhao-Xia Wang; Yao-Sheng Wang
Journal:  Front Cardiovasc Med       Date:  2022-03-07

Review 5.  Cardiovascular biomarkers in body fluids: progress and prospects in optical sensors.

Authors:  Reena V John; Tom Devasiya; Nidheesh V R; Sphurti Adigal; Jijo Lukose; V B Kartha; Santhosh Chidangil
Journal:  Biophys Rev       Date:  2022-08-18

Review 6.  A Review of Adrenomedullin in Pediatric Patients: A Useful Biomarker.

Authors:  Anna Solé-Ribalta; Sara Bobillo-Pérez; Iolanda Jordan-García
Journal:  Children (Basel)       Date:  2022-08-06

7.  Effect of exercise therapy on established and emerging circulating biomarkers in patients with heart failure: a systematic review and meta-analysis.

Authors:  Melissa J Pearson; Nicola King; Neil A Smart
Journal:  Open Heart       Date:  2018-07-11

8.  Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failure.

Authors:  Henrike Arfsten; Georg Goliasch; Philipp E Bartko; Suriya Prausmüller; Georg Spinka; Anna Cho; Johannes Novak; Helmuth Haslacher; Guido Strunk; Joachim Struck; Martin Hülsmann; Noemi Pavo
Journal:  Br J Clin Pharmacol       Date:  2020-07-20       Impact factor: 3.716

9.  Adrenomedullin Attenuates Inflammation in White Adipose Tissue of Obese Rats Through Receptor-Mediated PKA Pathway.

Authors:  Hang-Bing Dai; Fang-Zheng Wang; Ying Kang; Jing Sun; Hong Zhou; Qing Gao; Zhen-Zhen Li; Pei Qian; Guo-Qing Zhu; Ye-Bo Zhou
Journal:  Obesity (Silver Spring)       Date:  2020-09-28       Impact factor: 9.298

10.  Novel insights into peptide amidation and amidating activity in the human circulation.

Authors:  Paul Kaufmann; Andreas Bergmann; Olle Melander
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.